122
Views
7
CrossRef citations to date
0
Altmetric
Review

Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction

, , , &
Pages 2475-2479 | Published online: 21 Nov 2018

Abstract

Belimumab is a novel add-on therapy that has been approved for patients with active and antibody-mediated systemic lupus erythematosus. It is a monoclonal antibody that decreases the activation of B-cells and consequently decreases antibodies’ production. Recently, the US Food and Drug Administration approved subcutaneous belimumab for patients who have received training on using it. Subcutaneous belimumab can be administered using either a prefilled syringe or an auto-injector device. Weekly subcutaneous belimumab seems to be as effective as monthly intravenous belimumab with a similar safety margin. In this article, we reviewed the literature on subcutaneous belimumab focusing on safety and patients’ experiences and satisfaction. Overall, subcutaneous belimumab appears to be preferred over intravenous belimumab for a number of reasons. However, more studies are still required to prove these findings.

Introduction

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease associated with variable clinical presentations. Its prevalence in the US is estimated to be up to 150 patients per 100,000.Citation1 The disease typically runs a relapsing course and can result in multiple comorbidities.Citation2 Mortality may occur early in the course of the disease. Causes of mortality and morbidity include severe organ damage, infections as a result of suppressed immune system, and cardiovascular events secondary to accelerated atherosclerosis.Citation3 The precise etiology of SLE is not known and is postulated to be secondary to genetic, environmental, immune, and/or hormonal factors. However, despite the unclear etiology, it is known that most of the disease manifestations are mediated by the formation of different autoantibodies and antigen-antibody complexes.Citation4Citation8 This abundance of autoantibodies in SLE is reflective of a significant role of B-cell-mediated pathogenesis.Citation9

Earlier guidelines for SLE treatment recommended the use of antimalarial medications, nonsteroidal anti-inflammatory drugs, and corticosteroids.Citation10,Citation11 Later, immunosuppressant medications were recommended for specific systems’ involvement, severe disease, and as corticosteroid sparing agents.Citation12Citation14 Since 1998, hydroxychloroquine has been the only medication approved by the US Food and Drug Administration (FDA) for the treatment of SLE.Citation15,Citation16 In 2011, the FDA approved the use of belimumab for treatment of patients with antibody-positive active SLE without active lupus nephritis or central nervous system (CNS) involvement. In July 2017, the FDA approved the use of the subcutaneous (SC) form of belimumab by patients who received user training from their health care providers.Citation17

In this review, we used different combinations of keywords “Belimumab”, “Subcutaneous”, “Preference”, “Safety”, and “Efficacy” in PubMed, Cochrane, and Google Scholar to find studies and articles that discussed efficacy, safety, and patient preference of SC belimumab.

Belimumab

BAFF protein, known as B-cell lymphocyte stimulator, is a TNF that binds to different receptors in the B-cell resulting in proliferation, differentiation, and secretion of antibodies.Citation18,Citation19 Elevated levels of BAFF have been found in patients with SLE and have been linked to disease flares.Citation20Citation23 Belimumab is a human monoclonal IgG1 antibody that binds to BAFF protein resulting in a significant decrease in the number and activation of B-cells with a sequential decrease in autoantibodies’ production.Citation24,Citation25 Clinical trials have demonstrated that belimumab resulted in significant reduction of anti-dsDNA (double-stranded DNA) antibody, improvement of complement levels, and resolution of hypergammaglobulinemia.Citation26Citation29

SC belimumab

After the successful use of intravenous (IV) belimumab in the treatment of SLE,Citation30Citation35 the need for more convenient routes of administration, especially SC injection, has emerged.Citation36 Phase I studies demonstrated an acceptable bioavailability with different doses of SC belimumab. Moreover, weekly SC belimumab dosed at 200 mg achieved blood levels and bioavailability similar to those achieved by a monthly 10 mg/kg IV belimumab dose, regardless of the site of injection or body size. SC belimumab achieved maximum serum concentration within 3.9–5.9 days with a half-life of 18.2 days.Citation37Citation39 Phase II studies indicated an acceptable safety profile of SC belimumab similar to the IV form.Citation40Citation42

In a 52-week double-blinded, randomized controlled Phase III study (BLISS-SC), SC belimumab added to standard of care showed significantly higher efficacy, using SLE response index (SRI-4), time to severe flare, and corticosteroid dose reduction, compared to standard of care plus placebo.Citation43 Similar to IV belimumab, its efficacy was higher in a difficult-to-treat group of patients with positive anti-dsDNA and low complement level.Citation44 Moreover, in a 24-week open-label extension study that included 662 patients, SC belimumab continued to show the same efficacy.Citation45 Efficacy of SC belimumab was not different from IV belimumab when both were indirectly compared.Citation46 It is important to remember that only SLE patients with moderate to severe disease (score of ≥8 on the Safety of Estrogens in Lupus Erythematosus National Assessment version of the SLE Disease Activity Index) were included in all previously mentioned studies.Citation32,Citation33,Citation35,Citation43

Forms of SC belimumab

Currently, SC belimumab can be administered via either auto-injector or prefilled syringes. Both devices contain a single dose of 1 mL of preservative-free liquid solution (polysorbate 80, L-arginine hydrochloride, L-histidine, L-histidine monohydrochloride, and sodium chloride) in which 200 mg of belimumab is dissolved. Both devices come with a fixed 27-gage, half inch needle and are latex free.

SC belimumab should be stored at a temperature of 2°C–8°C (36–46°F). It should be allowed to warm at room temperature for 30 minutes before administration. SC tissue of both thighs and the abdomen (except for 2 cm around the umbilicus) are recommended as injection sites.Citation47

Safety of SC belimumab

In the 52-week BLISS-SC study, safety results in the belimumab group (556 patients) were comparable to the safety results in the placebo group (280 patients). Total adverse events were reported in 84% vs 80% in the placebo and the belimumab groups, respectively. Most common adverse events reported were infections. Serious adverse events were, surprisingly, reported more in the placebo group (15.7% vs 10.8%). As expected, treatment-related adverse events were higher in the belimumab group (31% vs 26%). Study discontinuation, due to adverse events, was more in the placebo group (8.9% vs 7.2%). Herpes zoster was reported more in the placebo group (4.6% vs 3.2%). There were three (0.5%) deaths in the belimumab group that resulted from bacterial sepsis, urosepsis, and CNS tuberculosis, and two (0.7%) deaths in the placebo group that were secondary to cardiac arrest and SLE-related thrombocytopenia.

Although local site injection reactions were reported more in the belimumab group, post-injection hypersensitivity reactions were reported more in the placebo group. It was noted that the adverse events, in general, were higher in patients with higher body weight in both groups but this finding was not explained. Depression was reported more in the placebo group (3.6% vs 2.7%). Suicidal ideation, with no execution/fatality, was reported in 0.4% of the belimumab patients.Citation43

Safety results continued to be similar in the group of patients with positive anti-dsDNA and low complement level. Total and treatment-related adverse events rates were similar to previously mentioned results. However, serious adverse events were higher in both treatment and placebo groups compared to the previously mentioned study, and continued to be higher in the placebo group (23.1% vs 13.3%).Citation44

Even after a 24-week extension of treatment, SC belimumab continued to be well tolerated and showed similar adverse events rates with lower treatment discontinuation rate.Citation45 SC belimumab resulted in less adverse events than IV belimumab; however, this was not statistically significant.Citation46

Patient satisfaction with SC belimumab using the auto-injector device

A two-part survey study evaluated the satisfaction of rheumatologists (N=88) and patients with SLE receiving treatment with and without belimumab (total N=513). It concluded that patient satisfaction was mainly driven by their ability to function on a daily basis while physician satisfaction with treatment was driven primarily by different clinical outcomes. Patients and physicians strongly agreed that improvement of fatigue was a significant component of satisfaction with treatment. The authors suggested that belimumab could be considered in patients who report dissatisfaction with their standard of care.

More than half of the patients who received belimumab preferred to self-administer their injectable medications at home and considered the convenience and flexibility of treatment administration vital drivers for satisfaction. This preference was higher among patients who were employed.Citation36

Another study that included 548 patients with SLE evaluated their preference for SC injection via an online survey. SC injection was the most preferred choice (41.2%) followed by IV infusions (36.9%). Surprisingly, 21.9% of the patients were not able to decide. Most patients in the latter group were the ones who did not have any previous experience with biological therapy. Older patients were more resistant to trying new SC injections. Patients who preferred SC injections emphasized the importance of not losing working days, avoiding going to the hospital, and being autonomous and comfortable at home. Those who expressed their preference for IV infusions emphasized the importance of feeling safe and the presence of qualified staff during therapy administration.

Despite the good number of study participants, it had some limitations as it relied only on patients who were able to use the internet and on their own interpretation of the questions and their knowledge.Citation48

We found only one study that assessed the patients’ experiences after using the auto-injector device for SC belimumab.Citation49 Forty-three patients who received IV belimumab and SC belimumab via prefilled syringes were switched to SC belimumab via auto-injector device and were followed-up for 2 months. The authors used a questionnaire and a semi-structured telephone interview at the beginning and the end of the eight weeks. Approximately 88% of the patients were very satisfied, and 12% were satisfied with the training they received for using the auto-injector device. By the end of the study, 83% of the patients felt extremely confident using the auto-injector device correctly. Approximately 70% of the patients were very satisfied, 26% were satisfied, and 5% were somewhat satisfied with using the auto-injector device.

The most common reported advantages of the auto-injector were convenience (71%), easy and quick administration (57%), and self-administration (24%). By the end of the study, patients endorsed more advantages: shorter administration time (38%), ease of incorporation into their daily routine (19%), and ability to administer at home (19%). On the other hand, 62% of the patients reported disadvantages including: injection-related discomfort, pain, stinging, nausea, and lack of control of injection speed. Pain was rated as mild in 83% of the patients, while 7% rated it as intermediate, and 10% rated it as severe. Other disadvantages included inconvenience which was explained by the need to store the medication in the refrigerator and the need to wait 30 minutes to achieve room temperature before using it.

Overall, 76% of the patients preferred the use of an auto-injector for SC belimumab over IV belimumab. Patients who preferred the IV form reported better control of their symptoms. In the same context, 52% reported no change in the severity of symptoms, while 24% reported improvement in symptoms that they thought was related to maintaining consistent levels of the medication with SC belimumab.

It is worth noting that the results from all previously mentioned studies could be biased as they relied on the memory recall of the patients included. Also, in such studies, patients may show higher compliance rates and their perspectives may be influenced by the fact that they are using new medication.

Conclusion

The majority of patients may prefer to use SC injections due to different reasons. Working status is a significant variable that may determine patients’ preference to use SC injections. Health care staff should provide sufficient training on SC injections’ administration and discuss their side effects and complications.

Data about SC belimumab were obtained from a limited number of studies. SC belimumab appears to be as effective as, and also as safe as, if not more so, than IV belimumab. SC belimumab is more convenient, time-saving, easier to use, and easier to incorporate into patients’ daily routines. These advantages were appreciated more by patients who were employed. Disadvantages of SC belimumab include discomfort and pain at the injection site, storage in the refrigerator, and the need to wait for the injector to warm-up prior to use.

Further head-to-head studies comparing IV belimumab, SC belimumab using auto-injector and prefilled syringes in a larger sample size and with a longer follow-up duration are still needed to confirm the results of these prelim inary data.

Acknowledgments

The authors would like to thank Bonita Archer, MLS, Cathey Carey, and Werner Medical Library staff for their help in reviewing the literature and gathering the articles used in this review.

Disclosure

The authors report no conflicts of interest in this work.

References

  • LawrenceRCHochbergMCKelseyJLEstimates of the prevalence of selected arthritic and musculoskeletal diseases in the United StatesJ Rheumatol19891644274412746583
  • FernandezDKirouKAWhat causes lupus flares?Curr Rheumatol Rep20161831426951252
  • CartellaSCavazzanaICeribelliAInverardiFTincaniAFranceschiniFEvaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosusAutoimmunity201346636336823706114
  • CooperGSDooleyMATreadwellELSt ClairEWGilkesonGSRisk factors for development of systemic lupus erythematosus: allergies, infections, and family historyJ Clin Epidemiol2002551098298912464374
  • BuyonJPPetriMAKimMYThe effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trialAnn Intern Med200514212 Pt 195396215968009
  • HahnBHEblingFSinghRRSinghRPKarpouzasGLa CavaACellular and molecular mechanisms of regulation of autoantibody production in lupusAnn N Y Acad Sci2005105143344116126985
  • ParksCGCooperGSOccupational exposures and risk of systemic lupus erythematosus: a review of the evidence and exposure assessment methods in population- and clinic-based studiesLupus2006151172873617153843
  • WongMTsaoBPCurrent topics in human SLE geneticsSpringer Semin Immunopathol20062829710716941108
  • MorawskiPABollandSExpanding the B Cell-Centric View of Systemic Lupus ErythematosusTrends Immunol201738537338228274696
  • Guidelines for referral and management of systemic lupus erythematosus in adultsAmerican College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus GuidelinesArthritis Rheum19994291785179610513791
  • BertsiasGIoannidisJPBoletisJEULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including TherapeuticsAnn Rheum Dis200867219520517504841
  • HahnBHMcMahonMAWilkinsonAAmerican College of Rheumatology guidelines for screening, treatment, and management of lupus nephritisArthritis Care Res2012646797808
  • Cobo-IbáñezTLoza-SantamaríaEPego-ReigosaJMEfficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic reviewSemin Arthritis Rheum201444217518524830791
  • WilhelmusSBajemaIMBertsiasGKLupus nephritis management guidelines comparedNephrol Dial Transplant201631690491325920920
  • AkhavanPSSuJLouWGladmanDDUrowitzMBFortinPRThe early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosusJ Rheumatol201340683184123588942
  • SugaiDYGustafsonCJDe LucaJFTrends in the outpatient medication management of lupus erythematosus in the United StatesJ Drugs Dermatol201413554555224809877
  • PohYJBaptistaBD’CruzDPSubcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administrationExpert Rev Clin Immunol2017131092593828847197
  • MoorePABelvedereOOrrABLyS: member of the tumor necrosis factor family and B lymphocyte stimulatorScience1999285542526026310398604
  • WuYBressetteDCarrellJATumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLySJ Biol Chem200027545354783548510956646
  • ZhangJRoschkeVBakerKPCutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosusJ Immunol2001166161011123269
  • StohlWMetyasSTanSMB lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observationsArthritis Rheum200348123475348614673998
  • CollinsCEGavinALMigoneTSHilbertDMNemazeeDStohlWB lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levelsArthritis Res Ther200681R616356193
  • PetriMStohlWChathamWAssociation of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosusArthritis Rheum20085882453245918668552
  • BakerKPEdwardsBMMainSHGeneration and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulatorArthritis Rheum200348113253326514613291
  • HalpernWGLappinPZanardiTChronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effectsToxicol Sci200691258659916517838
  • StohlWHiepeFLatinisKMBelimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosusArthritis Rheum20126472328233722275291
  • van VollenhovenRFPetriMACerveraRBelimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of responseAnn Rheum Dis20127181343134922337213
  • ManziSSánchez-GuerreroJMerrillJTEffects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsAnn Rheum Dis201271111833183822550315
  • FanouriakisAAdamichouCKoutsovitiSLow disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational studySemin Arthritis Rheum Epub2018223
  • FurieRStohlWGinzlerEMBiologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosusArthritis Res Ther2008105R10918786258
  • WallaceDJStohlWFurieRAA phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosusArthritis Rheum20096191168117819714604
  • NavarraSVGuzmánRMGallacherAEEfficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialLancet2011377976772173121296403
  • FurieRPetriMZamaniOA phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis Rheum201163123918393022127708
  • GinzlerEMWallaceDJMerrillJTDisease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosusJ Rheumatol201441230030924187095
  • ZhangFBaeSCBassDA pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South KoreaAnn Rheum Dis201877335536329295825
  • PascoeKLoboscoSBellDPatient- and Physician-reported Satisfaction With Systemic Lupus Erythematosus Treatment in US Clinical PracticeClin Ther20173991811182628803702
  • CaiWWFiscellaMChenCZhongZJFreimuthWWSubichDCBioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy SubjectsClin Pharmacol Drug Dev20132434935727121939
  • ShidaYTakahashiNSakamotoTInoHEndoAHiramaTThe pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteersJ Clin Pharm Ther20143919710124117862
  • YapaSWRothDGordonDStruemperHComparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 programLupus201625131448145527072354
  • StruemperHMurtaughTGilbertJRelative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy SubjectsClin Pharmacol Drug Dev20165320821527163500
  • SheikhSZHammerAEFoxNLEvaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosusInt J Clin Pharmacol Ther2016541191492227668697
  • StruemperHThaparMRothDPopulation Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus ErythematosusClin Pharmacokinet201857671772828887801
  • StohlWSchwartingAOkadaMEfficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled StudyArthritis Rheumatol20176951016102728118533
  • DoriaAStohlWSchwartingAEfficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypoco-mplementemic Patients With Systemic Lupus ErythematosusArthritis Rheumatol20187081256126429671280
  • DoriaABassDSchwartingAA 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosusLupus20182791489149829807477
  • RamachandranSParksDKurtineczMRothDAAlfonso-CristanchoRAn indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activityJ Comp Eff Res20187658159329692179
  • Benlysta® (belimumab) [prescribing information]Rockville (MD)GlaxoSmithKline Ltd2017
  • FalangaMCanzonaAMazzoniDPreference for Subcutaneous Injection or Intravenous Infusion of Biological Therapy Among Italian Patients With SLEJ Patient Exp2018237437351877081
  • Dashiell-AjeEHardingGPascoeKDevriesJBerryPRamachandranSPatient Evaluation of Satisfaction and Outcomes with an Autoinjector for Self-Administration of Subcutaneous Belimumab in Patients with Systemic Lupus ErythematosusPatient201811111912928956281